EPHX2

Across TCGA pan-cancer cohorts, EPHX2 mass-spec protein differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of EPHX2’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where EPHX2 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types EPHX2 is over-expressed in tumor, although a few such as CCRCC and HNSC show the opposite, repressed pattern.

CCRCC, HNSC, and COAD are the cancer types where EPHX2 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in EPHX2 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	All	IV	−1.191	<.001	12	view →
HNSC	All	IV	−1.521	<.001	11	view →
COAD	Female	III,IV	−1.025	<.001	11	view →
LSCC	Female	All	−0.963	<.001	9	view →
LUAD	Female	II,III,IV	−0.778	<.001	9	view →
PDAC	Female	All	−1.356	<.001	8	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 6 strongest of 6 lineages.

EPHX2–CCRCC

Open the CCRCC breakdown →